Physician profile
Gregory San
NPI 1679565279
$87,985.74
in general payments reported to CMS, 2019-2025
37 companies · $7,242 in 2025
The $7,242 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $10K · 2021: $9,756 · 2022: $16K · 2023: $6,905 · 2024: $9,402 · 2025: $7,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $3,044 · Travel and Lodging: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,280.00 |
| Food and Beverage | $3,044.30 |
| Travel and Lodging | $1,224.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49,306.12 | 2019-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29,801.57 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $1,141.40 | 2019-2025 | Avvigo Guidance System, Opticross, Watchman Flx |
| Abbott Laboratories | $858.80 | 2019-2023 | Confirm Rx |
| Janssen Pharmaceuticals, INC | $853.88 | 2019-2023 | Xarelto |
| Amgen INC. | $775.69 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $651.83 | 2019-2025 | |
| Abiomed | $588.92 | 2019-2025 | Impella |
| Medtronic, INC. | $481.32 | 2021-2025 | Symplicity G3, Azure Xt Dr Mri Surescan, Onyx Frontier |
| Medtronic Vascular, INC. | $396.74 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $393.47 | 2019-2024 | Farxiga, Andexxa |
| Pfizer INC. | $383.91 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $353.49 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $343.05 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $313.07 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $216.46 | 2019-2021 | |
| Gilead Sciences, INC. | $136.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $134.81 | 2019 | |
| Atricure, INC. | $113.47 | 2021-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| E.R. Squibb & Sons, L.L.C. | $107.80 | 2019-2025 | |
| Teleflex Medical Canada INC. | $96.80 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $76.72 | 2019-2022 | |
| Shockwave Medical, INC | $74.85 | 2022 | |
| Amarin Pharma, INC. | $70.28 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $43.40 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $39.60 | 2025 | Onpattro |
| Cvrx, INC. | $38.53 | 2023-2025 | Barostim Neo System |
| Novo Nordisk INC | $38.34 | 2019-2025 | Wegovy |
| Esperion Therapeutics, INC. | $34.14 | 2020-2023 | Nexletol |
| Cardiovascular Systems INC. | $29.03 | 2019-2020 | |
| Acist Medical Systems, INC. | $27.02 | 2025 | |
| Daiichi Sankyo INC. | $24.72 | 2023 | Injectafer |
| Lundbeck LLC | $17.60 | 2019 | |
| Terumo Medical Corporation | $12.46 | 2022 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory San listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.